Topical imiquimod therapy for actinic keratosis: is long-term clearance a realistic benefit?

, editors.

Affiliations

¹ Dr. James Del Rosso, DO, FAOCD is Dermatology Residency Director, Valley Hospital Medical Center; Clinical Associate Professor (Dermatology), University of Nevada School of Medicine, Las Vegas, Nevada; and Associate Professor (Dermatology), Touro University College of Osteopathic Medicine, Henderson, Nevada.

Editor:James Q. Del Rosso. J Clin Aesthet Dermatol. 2008 Sep.

. 2008 Sep;1(3):44-7.

¹ Dr. James Del Rosso, DO, FAOCD is Dermatology Residency Director, Valley Hospital Medical Center; Clinical Associate Professor (Dermatology), University of Nevada School of Medicine, Las Vegas, Nevada; and Associate Professor (Dermatology), Touro University College of Osteopathic Medicine, Henderson, Nevada.

No abstract available

Figures

1. Exton, PA: Graceway Pharmaceuticals; 2008. Aldara [package insert]
1. Del Rosso JQ. The treatment of viral infections and nonmelanoma skin cancers. Cutis. 2007;79(4 Suppl):29–35. - PubMed
1. Miller RI, Gerster JF, Owens MI, et al. Imiquimod applied topically: a novel immune response modifier and a new class of drug. Int J Immunopharmacol. 1999;21:1–14. - PubMed
1. Hemmi H, Kaisho T, Takuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196–200. - PubMed
1. Del Rosso JQ. The use of topical imiquimod for the treatment of actinic keratosis: a status report. Cutis. 2005;76:241–248. - PubMed